TransMedics Group (NASDAQ:TMDX) Trading Up 11.9% – Time to Buy?

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price traded up 11.9% during trading on Tuesday . The stock traded as high as $149.27 and last traded at $150.6250. 453,436 shares were traded during trading, a decline of 17% from the average session volume of 549,156 shares. The stock had previously closed at $134.66.

Analysts Set New Price Targets

TMDX has been the topic of several research analyst reports. Morgan Stanley lifted their price objective on TransMedics Group from $123.00 to $135.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Zacks Research cut shares of TransMedics Group from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 6th. Canaccord Genuity Group increased their price objective on shares of TransMedics Group from $147.00 to $148.00 and gave the stock a “buy” rating in a research report on Wednesday, December 17th. Needham & Company LLC raised their target price on shares of TransMedics Group from $148.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, December 8th. Finally, Piper Sandler reaffirmed an “overweight” rating on shares of TransMedics Group in a research report on Monday, December 22nd. Six equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $144.25.

TransMedics Group Stock Performance

The company has a market capitalization of $4.91 billion, a price-to-earnings ratio of 58.17 and a beta of 2.03. The company has a current ratio of 7.69, a quick ratio of 7.13 and a debt-to-equity ratio of 1.43. The stock has a 50-day simple moving average of $130.39 and a 200-day simple moving average of $122.57.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business’s quarterly revenue was up 32.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.12 earnings per share. On average, analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, Director David Weill sold 5,000 shares of TransMedics Group stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $138.64, for a total value of $693,200.00. Following the completion of the transaction, the director directly owned 12,134 shares in the company, valued at approximately $1,682,257.76. This trade represents a 29.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Basile sold 4,142 shares of the business’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total value of $540,323.90. Following the completion of the sale, the director directly owned 2,866 shares of the company’s stock, valued at approximately $373,869.70. This represents a 59.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 13,062 shares of company stock valued at $1,797,634 in the last 90 days. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors and hedge funds have recently bought and sold shares of the business. Opal Wealth Advisors LLC acquired a new position in TransMedics Group in the second quarter valued at approximately $26,000. Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of TransMedics Group by 981.0% in the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 227 shares of the company’s stock worth $26,000 after purchasing an additional 206 shares during the last quarter. Salomon & Ludwin LLC acquired a new position in TransMedics Group during the 3rd quarter valued at approximately $28,000. Harvest Fund Management Co. Ltd acquired a new position in TransMedics Group during the 3rd quarter valued at approximately $29,000. Finally, Optiver Holding B.V. grew its stake in TransMedics Group by 248.1% during the 3rd quarter. Optiver Holding B.V. now owns 268 shares of the company’s stock worth $30,000 after buying an additional 191 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.